Disease Overview：Benign Prostatic Hyperplasia（BPH）
Benign Prostatic Hyperplasia (BPH) is a non-malignant enlargement of the prostate gland commonly affecting men over 50. As the prostate grows, it compresses the urethra, leading to lower urinary tract symptoms—including urinary frequency, nocturia, weak stream, hesitancy, incomplete bladder emptying, and, in advanced cases, acute urinary retention or secondary complications like bladder stones or renal impairment. Diagnosis typically involves digital rectal examination, serum PSA testing, uroflowmetry, post-void residual volume assessment, and transrectal ultrasound or MRI when indicated. Management ranges from watchful waiting and medical therapy (e.g., alpha-blockers, 5-alpha-reductase inhibitors) to minimally invasive procedures such as transurethral resection of the prostate (TURP), holmium laser enucleation (HoLEP), or newer modalities like bipolar TURP and water vapor thermal therapy.
China offers distinct advantages for BPH treatment: its urology centers—especially tier-1 hospitals in Beijing, Shanghai, and Guangzhou—boast internationally trained specialists with extensive experience in complex and recurrent BPH cases. Advanced technologies including high-power green-light lasers, thulium lasers, and robotic-assisted platforms are widely deployed and validated through robust clinical outcomes data. Success rates for HoLEP and bipolar TURP exceed 92% in symptom relief and functional improvement, with low complication rates and shorter hospital stays. Crucially, treatment costs in China are typically 40–60% lower than in the US, UK, or Germany—without compromising safety or efficacy. As a dedicated medical tourism agency, we facilitate seamless access for international patients: vetting accredited hospitals, coordinating consultations and surgery scheduling, providing transparent itemized pricing, arranging visas and accommodation, and offering multilingual support throughout the care journey—from pre-travel assessment to postoperative follow-up.
Benign Prostatic Hyperplasia: treatment in China helps patients compare specialist hospitals, initial assessment steps and estimated costs that may vary by city, institution and clinical condition.
Medical Treatment Guide
Treatment Options & Itemized Cost Breakdown: Benign Prostatic Hyperplasia (BPH)
Non-Surgical / Conservative Management
*Indicated for mild-to-moderate symptoms (IPSS ≤19), no urinary retention, Qmax ≥10 mL/s, prostate volume <80 mL, no significant comorbidities.*
- •Alpha-blockers (e.g., tamsulosin): ¥45–¥120/month ($6–$17)
- •5-alpha reductase inhibitors (e.g., finasteride): ¥60–¥180/month ($8–$25)
- •Combination therapy: ¥100–¥300/month ($14–$42)
- •Baseline diagnostics: PSA test (¥120), transrectal ultrasound (TRUS) (¥380), uroflowmetry + post-void residual (PVR) (¥220) → Total: ¥720 ($100)
- •Annual monitoring: PSA + TRUS + symptom assessment → ¥650 ($91)
Surgical / Interventional Options
*Eligible for moderate-to-severe BPH (IPSS ≥20, Qmax <10 mL/s, recurrent UTI, bladder stones, renal impairment, or failed medical therapy).*
- •Transurethral Resection of the Prostate (TURP)
- Procedure + 3-day hospital stay (Grade 3A public hospital): ¥18,500–¥24,000 ($2,590–$3,360)
- •Holmium Laser Enucleation of the Prostate (HoLEP)
- Procedure + 2-day stay: ¥26,000–¥32,000 ($3,640–$4,480)
- •Transurethral Bipolar Enucleation (ThuLEP)
- Procedure + 2-day stay: ¥23,000–¥28,500 ($3,220–$3,990)
Special/Complex Condition Management
- •BPH with large prostate (>100 g) or bladder calculi: HoLEP preferred; add cystolitholapaxy (+¥3,500–¥5,200 / $490–$730).
- •BPH with chronic urinary retention requiring catheter dependence: Requires pre-op bladder training + urodynamics (¥1,800 / $252); TURP/HoLEP cost increases by ¥2,000–¥4,000 ($280–$560).
- •High-risk patients (severe CAD, anticoagulation): ThuLEP or laser vaporization (GreenLight PVP); PVP procedure cost: ¥21,000–¥27,500 ($2,940–$3,850).
Quick Selection Guide
- •Age <65, budget-constrained, IPSS 12–18: Start with alpha-blocker monotherapy ($6–$17/month) + annual monitoring ($91).
- •Age 65–80, moderate symptoms, prostate 40–75 g: TURP offers best long-term durability ($2,590–$3,360) and is covered by basic医保 (insurance).
- •Prostate >80 g or anticoagulated: HoLEP ($3,640–$4,480) — superior hemostasis, lower reoperation risk.
- •Severe comorbidities (COPD, heart failure): GreenLight PVP ($2,940–$3,850) — shorter catheter time, outpatient-capable in select centers.
- •Recurrent retention or renal impairment: Urgent HoLEP or ThuLEP; avoid delayed intervention—costs rise 20% if acute retention precedes surgery.
Pricing & Service Differences: International / VIP Dept vs. Regular Clinic
International Medical Services (IMS / VIP Departments) at Grade-3A public hospitals and private international clinics operate under self-regulated VIP fee schedules. Fees are higher than standard public clinics (which are subsidized solely for domestic citizens and do not accept overseas insurances). In exchange, international patients receive 6 exclusive medical privileges:
Recommended Hospitals
Explore selected Grade 3A public hospitals in China with rich clinical experience for this condition:
🌴 Recommended Benign Prostatic Hyperplasia Medical Vacation Packages
Curated transparent all-inclusive packages combining Benign Prostatic Hyperplasia treatment with China top medical destinations:
